In addition to the effect of ET-1 on cancer progression [9], ET-1 is known to contribute to other cardiovascular complications in non-cancer conditions including hypertension, left ventricular hypertrophy (LVH) and heart failure [13–16]. Here, EDN1 is linked to heart failure.